Related Experiment Video
Updated: Jan 30, 2026
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
10.2K
ReDO_DB: the repurposing drugs in oncology database
Pan Pantziarka1,2, Ciska Verbaanderd1,3, Vidula Sukhatme4
1The Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium.
Ecancermedicalscience
|January 26, 2019
Summary
Drug repurposing explores using existing non-cancer medications for cancer treatment. The Repurposing Drugs in Oncology (ReDO) project identified 268 drugs with anticancer activity, creating an open-access database for research.
Area of Science:
- Oncology
- Drug Development
- Pharmacology
Background:
- Drug repurposing is a strategy to find new uses for existing medications.
- There is growing interest in using non-cancer drugs to treat cancer.
- The Repurposing Drugs in Oncology (ReDO) project focuses on this area.
Purpose of the Study:
- To identify licensed non-cancer drugs with evidence of anticancer activity.
- To compile this information into a comprehensive database.
- To make the data accessible for further research and clinical application.
Main Methods:
- A literature-based approach was employed to identify relevant drugs.
- Data from numerous studies were systematically collected and analyzed.
- A database, ReDO_DB, was developed to store and present the findings.
Main Results:
- Data from 268 drugs with documented anticancer activity were collected.
- Summary results of identified drugs and their anticancer potential are outlined.
- An assessment of current clinical trial activity involving these repurposed drugs is included.
Conclusions:
- The ReDO project has created a valuable open-access resource (ReDO_DB) for cancer drug repurposing research.
- This database facilitates the exploration of existing non-cancer drugs as potential cancer therapies.
- The findings support further investigation into repurposed drugs for oncology indications.
Related Concept Videos
01:25Pharmacokinetics: Drug–Drug Interactions
435
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
435
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
157
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
157
01:26FDA Approved Drugs: Changes to Approved Drugs
268
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
268
01:27Factors Influencing Drug Absorption: Drug Dissolution
1.2K
The pharmacokinetic journey of drugs from solid oral dosage forms into systemic circulation is multifaceted. It begins with disintegration, a prerequisite ensuring a solid dosage form's subdivision into minute particles. Dissolution occurs next as these granulated entities solubilize in gastrointestinal fluids. This solubilization is crucial for the succeeding stage, permeation, which describes the traversal of the drug across the intestinal membrane and its subsequent entry into the blood...
1.2K
01:18Factors Affecting Protein-Drug Binding: Drug-Related Factors
479
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
479
01:26Pharmacokinetics: Drug–Food and Drug–Viral Interactions
243
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
243